Small-cell lung cancer is striking for its dramatic initial response to treatment. With standard platinum-based chemotherapy, 85 to 90 percent of patients experience rapid improvement in symptoms and a major reduction in tumour size. The challenge comes later: the disease frequently returns, often within months, and can progress so quickly that many patients are too unwell to receive a second-line
therapy.
Why this pattern is so difficult Small-cell lung cancer grows fast and adapts quickly. After responding to first-line chemotherapy, resistant cell populations can expand, and the disease may accelerate on relapse. Because recovery time is short and symptoms can escalate, a large proportion of patients never get the chance to try another active drug.
A new strategy presented in 2025 At the 2025 ASCO meeting, investigators evaluated lurbinectedin — a drug active in relapsed small-cell lung cancer — as maintenance therapy immediately after completion of first-line chemotherapy. The rationale is pragmatic: if many patients will not be fit enough for second-line treatment once relapse occurs, delivering an active agent earlier, while they are still well, may extend control.
What the study showed Maintenance lurbinectedin improved outcomes, with a reported hazard ratio of 0.73 for overall survival versus observation alone — a genuine signal in a field that has seen limited progress. As always, benefits must be weighed against side effects (including fatigue, low blood counts, and nausea), so quality-of-life results are essential to interpretation.
What this could mean for patients Maintenance therapy could become an important option for prolonging control after the initial response, keeping momentum while patients are at their strongest. Further studies will refine who benefits most, dosing schedules, and how to integrate imaging and blood-based monitoring.
Final thoughts Small-cell lung cancer remains one of oncology’s toughest challenges, with exhilarating initial wins and swift relapses. Maintenance strategies such as lurbinectedin offer realistic hope of longer, better-quality control.